NASDAQ$IRMD
IRadimed Corporation · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
IRadimed demonstrated revenue growth and profitability.
IRadimed Corporation reported a revenue of $13.4 million, a 23% increase compared to Q3 2021. The company's operating income increased by 32% to $4.1 million, and GAAP diluted EPS grew by 35% to $0.27. Strong demand for IV pump and patient monitor product lines continued with bookings exceeding revenues, adding to the company's backlog.
- Revenue was $13.4 million, up 23% year-over-year.
- Operating income reached $4.1 million, a 32% increase.
- GAAP diluted EPS was $0.27, reflecting a 35% growth.
- Operating cash flow was $3.9 million.
Headline financials
Revenue & EPS history
IRadimed · Revenue · Quarterly
$13.4M
Forward guidance
The Company expects to report revenue of $14.1 million to $14.8 million and GAAP diluted earnings per share of $0.23 to $0.28 per share for the fourth quarter of 2022.
Tailwinds
- Expects revenue of $14.1 million to $14.8 million for Q4 2022.
- Full-year revenue expected to be $52.5 million to $53.2 million.
- GAAP diluted earnings per share of $0.23 to $0.28 per share expected for Q4 2022.
- Full-year GAAP diluted earnings per share expected to be $0.95 to $1.00.
- Non-GAAP diluted earnings per share of $0.25 to $0.30 expected for Q4 2022.
Headwinds
- Non-GAAP diluted earnings per share guidance excludes stock-based compensation expense.
- Potential disruptions in the limited supply chain for products.
- Reliance on a limited number of products.
- Actions of the FDA or other regulatory bodies that could delay, limit or suspend product development, manufacturing or sales.
- Difficulties or delays in the development, production, manufacturing and marketing of new or existing products and services.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+2.2%
Avg return
Earnings day
+2.0%
Avg return
5 days after
+2.8%
Avg return
30 days after
59%
30 / 51 earnings
Positive
+32.1%
Q2 2019
Best reaction
-20.0%
Q1 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.5% | +3.4% | +8.6% | |
| Q4 2025 | +9.6% | +4.0% | +3.5% | |
| Q3 2025 | +9.4% | +9.8% | +21.3% | |
| Q1 2025 | -2.3% | -3.0% | +13.7% | |
| Q4 2024 | -8.4% | -5.8% | -13.3% | |
| Q3 2024 | -8.8% | -0.4% | +1.9% | |
| Q2 2024 | -4.9% | -6.6% | +0.5% | |
| Q1 2024 | +6.4% | +4.0% | +1.1% | |
| Q4 2023 | -6.9% | -3.3% | -5.2% | |
| Q3 2023 | +3.5% | -1.3% | +3.5% | |
| Q2 2023 | +10.7% | +10.4% | +9.7% | |
| Q1 2023 | +8.5% | +8.3% | +13.0% | |
| Q4 2022 | +10.1% | -0.3% | +3.7% | |
| Q3 2022 | +5.2% | +6.0% | +9.4% | |
| Q2 2022 | -1.4% | -3.2% | -17.8% | |
| Q1 2022 | -17.2% | -21.5% | -19.4% | |
| Q4 2021 | +19.8% | +33.5% | +24.1% | |
| Q3 2021 | +6.4% | +5.1% | +16.8% | |
| Q2 2021 | +1.0% | -1.8% | -2.2% | |
| Q1 2021 | +5.9% | +9.2% | +3.9% | |
| Q4 2020 | -7.2% | -2.4% | -7.8% | |
| Q3 2020 | +3.1% | +2.7% | +9.0% | |
| Q2 2020 | -4.2% | -2.7% | -7.2% | |
| Q1 2020 | -7.9% | -8.4% | +8.1% | |
| Q4 2019 | +2.4% | -0.5% | -10.8% | |
| Q3 2019 | +5.5% | +1.9% | -8.2% | |
| Q2 2019 | +32.1% | +23.6% | +7.1% | |
| Q1 2019 | -20.0% | -15.1% | -25.3% | |
| Q4 2018 | -0.4% | -0.9% | -12.4% | |
| Q3 2018 | +1.7% | +4.8% | +16.1% | |
| Q2 2018 | +4.6% | +9.8% | +17.5% | |
| Q1 2018 | +13.6% | +15.1% | +17.0% | |
| Q4 2017 | -6.3% | -7.3% | -13.6% | |
| Q3 2017 | +12.2% | +7.1% | +11.0% | |
| Q2 2017 | +17.3% | +14.9% | +18.5% | |
| Q1 2017 | -3.4% | -3.4% | -6.2% | |
| Q4 2016 | -4.0% | -2.8% | -2.8% | |
| Q3 2016 | +2.2% | +0.5% | +22.7% | |
| Q2 2016 | +2.8% | -4.6% | -1.2% | |
| Q1 2016 | -5.6% | — | — | |
| Q4 2015 | -17.1% | — | — | |
| Q3 2015 | +11.6% | — | — | |
| Q1 2014 | +0.2% | — | — | |
| Q2 2015 | +18.6% | — | — | |
| Q1 2015 | +2.2% | — | — | |
| Q4 2014 | +7.2% | — | — | |
| Q3 2013 | +4.9% | — | — | |
| Q3 2014 | +4.9% | — | — | |
| Q4 2013 | -2.3% | — | — | |
| Q2 2013 | -2.3% | — | — | |
| Q2 2014 | -0.4% | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro